Federation des caisses Desjardins du Quebec’s Briacell Therapeutics BCTX Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio BCTX Stock Details BCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.44K	Sell	450 -5	-1%	-$18	﹤0.01%	2777
2026 Q1	$1.66K	Sell	455 -750	-62%	-$3.49K	﹤0.01%	2695
2025 Q4	$8.57K	Buy	1,205 +300	+33%	+$3.17K	﹤0.01%	2312
2025 Q3	$9.84K	Buy	905 +555	+159%	+$5.83K	﹤0.01%	2274
2025 Q2	$10.2K	Buy	+350	New	+$12.8K	﹤0.01%	2037

Other funds holding BCTX

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

LCM

LuminArx Capital Management New York $224M AUM

National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's BCTX Position: Q2 2026 in Review

Federation des caisses Desjardins du Quebec reduced its Briacell Therapeutics (BCTX) stake by 1.1% in Q2 2026, selling an estimated $18 and leaving 450 shares worth $1.44K. The position accounts for ﹤0.01% of the portfolio, ranked #2777.

Federation des caisses Desjardins du Quebec first reported a position in BCTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $10.2K in Q2 2025. 19 funds tracked by Wall St. Rank hold BCTX as of Q2 2026.

Federation des caisses Desjardins du Quebec held 450 shares of Briacell Therapeutics worth $1.44K as of Q2 2026.
Federation des caisses Desjardins du Quebec sold 5 Briacell Therapeutics shares in Q2 2026, an estimated $18.
Briacell Therapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q2 2026, its #2777 holding.
Federation des caisses Desjardins du Quebec first reported a position in Briacell Therapeutics in Q2 2025 and has held it in 5 quarters since.
Federation des caisses Desjardins du Quebec's Briacell Therapeutics position peaked at $10.2K in Q2 2025.
19 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q2 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2026, filed 14 Aug 2026.